文献速递乳腺癌妇科肿瘤

BRCA1与BRCA2致病性变异携带者且有乳腺癌个人史者行双侧输卵管卵巢切除术的长期健康结局:基于链接电子健康记录的回顾性队列研究

Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records.
PubMed 文献 · Lancet Oncol · 2025-05-08

该回顾性队列研究利用英国国家癌症登记数据集与电子健康记录链接,纳入1995-2019年首次原发乳腺癌的3423例BRCA1/BRCA2致病性变异携带者,中位随访5.5年。结果显示双侧输卵管卵巢切除术(BSO)与BRCA1和BRCA2携带者全因死亡率降低相关(HR 0.52,95%CI 0.41-0.64),并与乳腺癌特异性死亡率降低相关。研究支持向有乳腺癌个人史的BRCA1/BRCA2致病性变异携带者提供BSO。

要点

  • BSO与BRCA1和BRCA2携带者全因死亡率降低相关(HR 0.52,95%CI 0.41-0.64)。
  • BSO与乳腺癌特异性死亡率降低相关(BRCA1 HR 0.62,95%CI 0.42-0.92;BRCA2 HR 0.48,95%CI 0.34-0.68)。
  • BSO与第二非乳腺癌风险降低相关(HR 0.59,95%CI 0.37-0.94),未增加心血管疾病等风险。

核心结论

  • 证据支持向有乳腺癌个人史的BRCA1和BRCA2致病性变异携带者提供BSO,因其似乎从该手术中获益,且无证据表明长期不良健康结局风险增加。

研究设计与样本

  • 回顾性队列研究,链接英国国家癌症登记数据集(NCRD)与基因检测实验室数据及医院 Episode Statistics-Admitted Patient Care(HES-APC)数据集。
  • 纳入1995-2019年首次原发乳腺癌诊断、年龄20-75岁的女性,共1674例BRCA1、1740例BRCA2及9例BRCA1和BRCA2携带者。
  • 中位随访5.5年(IQR 3.4-8.2),采用多变量插补链式方程处理缺失数据,多变量Cox回归分析关联。

主要发现

  • 研究人群(n=3423)中3002例(88.7%)为白人,170例(5.0%)为亚裔,59例(1.7%)为黑人,26例(0.8%)为混合族裔,74例(2.2%)为其他族裔,92例(2.7%)族裔缺失。
  • 黑人女性BSO uptake显著低于白人女性(OR 0.48,95%CI 0.34-0.67),亚裔女性亦较低(OR 0.47,95%CI 0.27-0.82)。
  • 居住于社会经济剥夺最少地区的女性BSO uptake较高(OR vs 剥夺最多地区 1.38,95%CI 1.10-1.72)。
  • BSO与BRCA1和BRCA2携带者全因死亡率降低相关(HR 0.52,95%CI 0.41-0.64),与乳腺癌特异性死亡率降低相关(BRCA1 HR 0.62,95%CI 0.42-0.92;BRCA2 HR 0.48,95%CI 0.34-0.68)。
  • BSO与合并样本第二非乳腺癌风险降低相关(HR 0.59,95%CI 0.37-0.94);与心血管疾病(HR 0.73,95%CI 0.53-1.01)、缺血性心脏病(1.04,0.48-2.26)、脑血管疾病(0.32,0.11-0.90)、非乳腺癌特异性死亡(0.72,0.45-1.16)、对侧乳腺癌(1.18,0.64-2.16)或抑郁(0.94,0.62-1.42)风险增加无关。

临床怎么用

  • 作者结论认为证据支持向有乳腺癌个人史的BRCA1和BRCA2致病性变异携带者提供BSO。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Carriers of BRCA1 and BRCA2 pathogenic variants are at elevated risk of developing breast and ovarian cancers. To mitigate ovarian cancer risk, bilateral salpingo-oophorectomy (BSO) is commonly recommended for unaffected carriers and those with personal breast cancer history. Assessing BSO's long-term health outcomes in carriers with previous breast cancer history is essential. This study aims to examine the association between BSO and long-term health outcomes in individuals carrying pathogenic variants in BRCA1 and BRCA2 and with personal history of breast cancer. METHODS: Data from the National Cancer Registration Dataset (NCRD) were linked with data from genetic testing laboratories to identify carriers of BRCA1 and BRCA2 pathogenic variants affected by breast cancer using pseudonymised patient identifiers. Further linkage to the Hospital Episode Statistics-Admitted Patient Care (HES-APC) dataset identified patients who had undergone BSO. Women aged 20-75 years, with a diagnosis of breast cancer as their first primary malignancy in 1995-2019 were eligible. Long-term health outcomes were identified from HES-APC and NCRD. Missing data were imputed using multivariate imputations by chained equations. Multivariable Cox regression was used to examine the associations with mortality (all-cause mortality, breast cancer-specific mortality, and non-breast cancer-specific mortality), second non-breast cancer, cardiovascular diseases, ischaemic heart disease, cerebrovascular diseases, contralateral breast cancer, and depression. Analyses were adjusted for age at diagnosis, diagnosis year, ethnicity, deprivation index, tumour characteristics, Charlson comorbidity index, cancer treatment, and second cancer diagnosis before the start of follow-up. FINDINGS: We included 1674 BRCA1, 1740 BRCA2, and nine BRCA1 and BRCA2 carriers who were diagnosed with breast cancer between 1995 and 2019, with median follow-up time of 5·5 years (IQR 3·4-8·2). The study population (n=3423) consisted of 3002 (88·7%) White, 170 (5·0%) Asian, 59 (1·7%) Black, 26 (0·8%) mixed, and 74 (2·2%) other ethnic groups, and 92 (2·7%) had missing ethnicity. The uptake of BSO was significantly lower among Black women (odds ratio [OR] vs White women 0·48, 95% CI 0·34-0·67), and Asian women (0·47, 0·27-0·82). BSO uptake was higher in women living in the least socioeconomically deprived areas (OR vs most deprived 1·38, 95% CI [1·10-1·72]). BSO was associated with a reduced risk of all-cause mortality for both BRCA1 and BRCA2 pathogenic variant carriers (HR 0·52, 95% CI 0·41-0·64) and reduced breast cancer-specific mortality (BRCA1: HR 0·62, 95% CI 0·42-0·92 and BRCA2: 0·48, 0·34-0·68). It was also associated with a reduced risk of second non-breast cancer in the combined BRCA1 and BRCA2 sample (HR 0·59, 95% CI 0·37-0·94). There BSO was not associated with increased risk of cardiovascular diseases (HR 0·73, 95% CI 0·53-1·01), ischaemic heart disease (1·04, 0·48-2·26), cerebrovascular disease (0·32, 0·11-0·90), non-breast cancer specific mortality (0·72, 0·45-1·16), contralateral breast cancer (1·18, 0·64-2·16), or depression (0·94, 0·62-1·42). INTERPRETATION: The evidence supports offering BSO to BRCA1 and BRCA2 pathogenic variant carrriers with a personal history of breast cancer, as they appear to benefit from having the procedure, without evidence of an increased risk of adverse long-term health outcomes. FUNDING: Cancer Research UK.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Hassan H, Allen I, Rahman T, et al. Long-term health outcomes of bilateral salpingo-oophorectomy in BRCA1 and BRCA2 pathogenic variant carriers with personal history of breast cancer: a retrospective cohort study using linked electronic health records. Lancet Oncol. 2025. PMID: 40347974. doi:10.1016/S1470-2045(25)00156-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。